Recent studies suggest that MGMT expression not only affects tumor sensitivity to therapy but also plays a nuanced role in shaping the TIME, particularly in glioblastoma and other aggressive malignancies [23–25] (Figure 2). This evidence concerns the gene MGMT and glioblastoma.